Drug Profile
Ethyl eicosapentaenoic acid/rosuvastatin
Alternative Names: AMR-102; Ethyl eicosapentaenoic acid/rosuvastatin - Amarin; Icosapent ethyl/rosuvastatin - Amarin; Vascepa/rosuvastatin - AmarinLatest Information Update: 13 Mar 2023
Price :
$50
*
At a glance
- Originator Amarin Corporation
- Class Antidementias; Antihyperlipidaemics; Antineoplastics; Antiplatelets; Antivirals; Eicosanoids; Esters; Fluorobenzenes; Omega 3 fatty acids; Pyrimidines; Reactive oxygen species; Small molecules; Sulfonamides; Vascular disorder therapies
- Mechanism of Action HMG-CoA reductase inhibitors; Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Hyperlipidaemia
Most Recent Events
- 13 Mar 2023 Phase I clinical trial is still ongoing in Hyperlipidaemia in USA (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hyperlipidaemia in USA (PO)
- 21 Jun 2013 Safety and pharmacokinetics data from a phase I trial in healthy volunteers released by Amarin